Long-COVID / post-viral
The one rigorously-trialed peptide (aviptadil) failed; prioritize plausibility + safety.
Decision support, not prescription. You decide.
Warning — BPC-157 crash risk in post-viral/ME-CFS
Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.
Candidate agents
3 agents · ranked by role, then evidenceBest rationale but conflicting human data (mortality benefit in acute COVID; harm signal in a cohort).
PMID 378455988 reports · Strongest LC reports: fatigue/brain-fog resolution; effect lasts 48-72h
Aviptadil (VIP) FAILED primary endpoints in acute COVID (TESICO); never trialed for long-COVID.
PMID 37348524Warning — BPC-157 crash risk in post-viral/ME-CFS
4 reports · ~10% baseline lift; crash risk in severe ME/CFS
Matching protocol templates
Browse all →Neuroimmune balance and fatigue recovery
Immune recalibration and systemic recovery
Immune reset, energy restoration, and cytokine balance in autoimmune or fatigue syndromes
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.